Milestone Pharmaceuticals
Yahoo Finance • 6 hours ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Quantum Cyber (NASDAQ:QUCY) shares increased by 55.0% to $0.5 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.0 million. SELLAS Life Sciences Gr (NASDAQ:SLS) shares increased by 21.26%... Full story
Yahoo Finance • last month
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
MONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today an... Full story
Yahoo Finance • 2 months ago
Etripamil Drives Milestone Pharma's Q4 Revenue; Eyes EMA Marketing Approval In H1,2027; Stock Up
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST), a commercial-stage biopharmaceutical company, reported fourth-quarter and full-year 2025 results and provided corporate updates for its lead product, CARDAMYST(Etripamil). Company profile... Full story
Yahoo Finance • 2 months ago
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT
FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so m... Full story
Yahoo Finance • 2 months ago
Here are the major earnings before the open Friday
Major earnings expected before the bell on Friday include: * Milestone Pharmaceuticals (MIST [https://seekingalpha.com/symbol/MIST]) * Westwater Resources (WWR [https://seekingalpha.com/symbol/WWR]) * XPeng (XPEV [https://seekingalp... Full story
Yahoo Finance • 5 months ago
Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval
As previously reported, TD Cowen upgraded Milestone Pharmaceuticals (MIST) to Buy from Hold with an $8 price target after Cardamyst nasal spray was approved by the FDA for the conversion of acute symptomatic episodes of paroxysmal supraven... Full story
Yahoo Finance • 5 months ago
MIST Hits A Milestone: FDA Approves First-Ever Self-Administered Nasal Spray For PSVT
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has received FDA approval for its first commercial product, CARDAMYST nasal spray, for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhyth... Full story
Yahoo Finance • 5 months ago
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 30,000 option... Full story
Yahoo Finance • 6 months ago
Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects
Milestone Pharmaceuticals (NASDAQ:MIST) is one of the Canadian penny stocks to buy right now. On November 13, analysts at Jefferies reiterated a Hold rating on Milestone Pharmaceuticals (NASDAQ: MIST) and raised the price target to $2 from... Full story
Yahoo Finance • 6 months ago
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
PDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT) Promotional Launch Plans Set with Quick-Start Capability Upon Potential FDA Approval $82.6 million in Cash at... Full story
Yahoo Finance • 6 months ago
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
MONTREAL and CHARLOTTE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today an... Full story
Yahoo Finance • 7 months ago
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today ann... Full story
Yahoo Finance • 9 months ago
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved Public Offering Raised Tot... Full story
Yahoo Finance • 10 months ago
Milestone Pharmaceuticals Launches Public Offering To Support Etripamil Development
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) has initiated an underwritten public offering of its common shares, Series A and Series B warrants for purchasing common shares, and, for certain investors, pre-funded warrants in place of... Full story
Yahoo Finance • 10 months ago
Milestone Pharmaceuticals prices $52.5 million public offering
MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company with a market capitalization of $118 million, has priced its previously announced underwritten public offering at $1.50 per share, expected to r... Full story
Yahoo Finance • 10 months ago
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medic... Full story
Yahoo Finance • 10 months ago
Milestone Pharmaceuticals stock plunges on public offering announcement
Investing.com -- Milestone Pharmaceuticals Inc (NASDAQ:MIST) stock tumbled 30% after the company announced plans for an underwritten public offering of common shares and warrants. The biopharmaceutical company said it will offer common... Full story
Yahoo Finance • 10 months ago
Milestone Pharmaceuticals Announces Proposed Public Offering
MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the “Offering”) of its common sha... Full story
Yahoo Finance • 10 months ago
Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Mi... Full story
Yahoo Finance • 11 months ago
Milestone Pharmaceuticals submits response to FDA for PSVT drug
MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a $109.52 million market cap biotech company trading at $1.65 per share, has submitted its response to the U.S. Food and Drug Administration’s Complete Response Letter rega... Full story